Join
Live feed
·
PRReleasevia Quantisnow
Larimar Therapeutics Inc. logo

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial's 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich's Ataxia and First Quarter 2023 Financial Results

ByQuantisnow·Wall Street's wire, on your screen.
LRMR· Larimar Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LRMR (Larimar Therapeutics Inc.) and more on Quantisnow.